Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

This innovative model preserves the characteristics of ... Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin ...

Earth’s Lowest Point The Dead Sea, often termed nature’s paradox, holds the title of being the lowest point on Earth's ...

H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...

Baseline demographics, disease characteristics and disease severity were generally ... dactylitis and spondylitis), psoriasis, physical function, pain, fatigue and quality of life. Despite the advent ...

Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...